FILGRASTIM
Hemochromatosis
St. Jude Children's Research Hospitalprotein_peptidePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hemochromatosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deferasirox Haukeland University Hospital | Phase 4 | BBB |
DESFERRIOXAMINE B Boston Children's Hospital | Phase 4 | BB |
Hydroxyurea St. Jude Children's Research Hospital | Phase 3 | B |
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →